Illumina, Inc. (NASDAQ:ILMN) Receives Average Rating of “Hold” from Brokerages

Illumina, Inc. (NASDAQ:ILMN) has earned an average rating of “Hold” from the seventeen ratings firms that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $188.40.

ILMN has been the topic of a number of recent analyst reports. Barclays raised their price target on shares of Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a report on Friday, July 31st. Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Leerink Partners raised their target price on shares of Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a research note on Friday, July 17th. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $215.00 price target on shares of Illumina in a report on Friday, July 31st. Finally, Citigroup upped their price target on Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research report on Monday, August 3rd.

Insider Activity at Illumina

In other news, Director Keith A. Meister sold 457,858 shares of the business’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the sale, the director owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. The trade was a 16.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the transaction, the senior vice president owned 14,023 shares in the company, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 2,095,958 shares of company stock valued at $401,720,974 in the last ninety days. Corporate insiders own 2.90% of the company’s stock.

Institutional Trading of Illumina

Institutional investors have recently bought and sold shares of the stock. Fiduciary Financial Advisors purchased a new position in shares of Illumina in the second quarter worth $26,000. Keating Financial Advisory Services Inc. acquired a new stake in shares of Illumina during the second quarter worth $32,000. Rakuten Securities Inc. purchased a new stake in shares of Illumina during the second quarter valued at $33,000. Elyxium Wealth LLC purchased a new stake in shares of Illumina during the fourth quarter valued at $25,000. Finally, TD Waterhouse Canada Inc. acquired a new position in shares of Illumina in the 4th quarter valued at $26,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina News Summary

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s latest quarterly results exceeded expectations, with earnings of $1.31 per share versus the $1.23 consensus estimate and revenue of $1.16 billion versus expectations of $1.13 billion. Revenue increased 9.4% year over year, while fiscal 2026 EPS guidance remains $5.30-$5.40. Illumina stock information
• Positive Sentiment: Several institutional investors increased their positions, including Marshall Wace, Cresset Asset Management and Empowered Funds. Hedge funds and other institutions collectively own approximately 89.4% of ILMN shares, indicating strong professional-investor participation.
• Neutral Sentiment: Analyst opinions remain mixed. Zacks Research upgraded the stock to “strong buy,” and Leerink Partners raised its target to $210, while Deutsche Bank downgraded the shares to “hold.” The overall consensus rating is “hold,” with an average target of $188.40—below recent trading levels. Analyst coverage of Illumina
• Negative Sentiment: Director Keith A. Meister sold 679,574 Illumina shares from August 19 through August 21 for approximately $145.6 million. The transactions reduced his ownership by roughly one-third, although he still holds about 1.41 million shares. The size and timing of the sales may raise concerns about insider conviction, even though the filings do not establish the reason for the transactions. SEC insider ownership filing
• Negative Sentiment: SVP Christensen Jakob Wedel also sold 1,033 shares under a pre-arranged Rule 10b5-1 trading plan. The smaller, planned transaction is less concerning than Meister’s sales but adds to the recent pattern of insider selling. Illumina insider trading alert

Illumina Trading Up 2.9%

ILMN opened at $219.40 on Tuesday. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The firm has a market cap of $33.13 billion, a price-to-earnings ratio of 40.93, a PEG ratio of 3.09 and a beta of 1.45. Illumina has a 12 month low of $88.00 and a 12 month high of $220.43. The stock has a fifty day moving average price of $188.01 and a 200-day moving average price of $152.44.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter last year, the company earned $1.19 earnings per share. The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities research analysts anticipate that Illumina will post 5.36 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.